secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023837
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio doses first patient with nula-cel; Q3 net loss $24.7M; cash runway into Q4 2024
--------------------------------------------------------------------------------

- Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023.
- Q3 net loss $24.7M ($0.45 per share); R&D expenses $18.3M, G&A $7.9M.
- Cash, equivalents and investments $305.1M as of Sep 30, 2022; runway into Q4 2024.
- Entered strategic manufacturing partnership with WuXi Advanced Therapies for nula-cel.
- Two abstracts accepted for ASH 2022; hired Darren Hart as SVP of development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/0000950170-22-023837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022023837/grph-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer